cefoxitin | 1011402-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: cefoxitin
• 英文别名: 3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• CAS: 1011402-89-3
• 化学式: C₁₆H₁₇N₃O₇S₂
• 分子量: 427.459
• InChiKey: WZOZEZRFJCJXNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  202
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  cefoxitin 生成 3-(Hydroxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  MINEH, MASATOSI;KINOSITA, AKIO, GEHKKAN YAKUDZI, 31,(1989) N, S. 991-999

  摘要：

  DOI：
• 作为产物：
  描述：

  Sodium 3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 、 水 生成 cefoxitin
  参考文献：
  名称：

  MINEH, MASATOSI;KINOSITA, AKIO, GEHKKAN YAKUDZI, 31,(1989) N, S. 991-999

  摘要：

  DOI：

文献信息

• HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS
  申请人：Techfields Pharma Co., Ltd.

  公开号：EP2849738A1

  公开（公告）日：2015-03-25
• [EN] COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS<br/>[FR] COMPOSES DE COBALAMINE UTILISES COMME AGENTS ANTIBIOTIQUES ET COMME AGENTS D'IMAGERIE
  申请人：MAYO FOUNDATION

  公开号：WO2001092288A2

  公开（公告）日：2001-12-06

  The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a microbial infection.
• [EN] HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT À FORTE PÉNÉTRATION ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE POUR LE TRAITEMENT D'AFFECTIONS PULMONAIRES
  申请人：TECHFIELDS PHARMA CO LTD

  公开号：WO2013170655A1

  公开（公告）日：2013-11-21

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.